Trial Profile
Efficacy of nivolumab in patients with advanced lung adenocarcinoma predicted by CYFRA 21-1
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Mar 2018 New trial record
- 01 Feb 2018 Results published in the Tumour Biology.